2022 World Conference on Lung Cancer (ePosters)-EP14.01-021. Anlotinib Plus Irinotecan or Docetaxel in Small-Cell Lung Cancer (SCLC) Relapsed within Six Months: a Single-Arm Phase II Study

EP14.01-021. Anlotinib Plus Irinotecan or Docetaxel in Small-Cell Lung Cancer (SCLC) Relapsed within Six Months: a Single-Arm Phase II Study

Back to course

Pdf Summary

This study aimed to evaluate the efficacy and safety of anlotinib, a multitarget tyrosine kinase inhibitor, in combination with irinotecan or docetaxel for the treatment of small-cell lung cancer (SCLC) patients who had relapsed within six months after first-line treatment. The study included 32 patients who were eligible for efficacy analysis. The primary endpoint was objective response rate (ORR), and secondary endpoints included progression-free survival (PFS), disease control rate (DCR), overall survival (OS), and safety.<br /><br />The results showed that among the 32 patients, one patient (3.1%) achieved a complete response (CR), 19 patients (59.4%) achieved a partial response (PR), 10 patients (31.3%) had stable disease (SD), and two patients (6.2%) had disease progression (PD). The ORR was 62.5%, and the DCR was 93.8%. The median PFS was 4.5 months, and the median OS was 7.2 months. These findings indicate that anlotinib plus irinotecan or docetaxel showed promising efficacy in SCLC patients who relapsed within six months after first-line treatment.<br /><br />In terms of safety, the most common grade 1-2 treatment-related adverse events (TRAEs) included weakness, anorexia, anemia, leucopenia, and hypertension. Grade 3 TRAEs included leukopenia, thrombocytopenia, and anemia. Overall, the combination therapy was found to have manageable toxicities.<br /><br />In conclusion, anlotinib plus irinotecan or docetaxel demonstrated promising efficacy and manageable toxicities in SCLC patients who had relapsed within six months after first-line treatment. This combination therapy may serve as a potential novel therapeutic strategy for this patient population. Further research is needed to confirm these findings and provide more insights into the treatment of relapsed SCLC.

Asset Subtitle

Bing Xia

Meta Tag

Speaker Bing Xia

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - Informing ES-SCLC

Keywords

anlotinib

tyrosine kinase inhibitor

SCLC

small-cell lung cancer

relapsed

first-line treatment

irinotecan

docetaxel

efficacy

safety